Improved Bowel Preparation Method for Colonoscopy Based on Different Risk Stratification

Sponsor
Renmin Hospital of Wuhan University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04582942
Collaborator
Hubei Hospital of Traditional Chinese Medicine (Other), Wuhan Central Hospital (Other), Wuhan Third Hospital (Other), The General Hospital of Central Theater Command (Other), The Third People's Hospital of Hubei (Other), Wuhan Puren Hospital (Other), Wuhan Puai Hospital (Other), Tian You Hospital Affiliated to Wuhan University of Science and Technology (Other), Wuhan Red Cross Hospital (Other)
2,028
1
2
9.8
207.1

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the efficacy of polyethylene glycol(PEG) combined with lactulose for bowel preparation before colonoscopy in low-risk patients and high-risk patients.

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

The quality of bowel preparation is crucial for colonoscopy. Some high-risk factors for inadequate bowel preparation have been identified , including age >70, previous colon surgery, constipation, diabetes, Parkinson's disease, history of stroke or spinal cord injury, prior history of inadequate bowel preparation, body mass index (BMI) >25, use of tricyclic antidepressant or narcotics. Patients were considered as low risk if they any of the above factors and considered as low risk if they did not have any of these risk factors.This is a multicenter, endoscopist-blinded study to compare the efficacy of PEG combined with lactulose and PEG alone in bowel preparation. In colonoscopy procedures, endoscopists who were blinded to the intervention evaluated the overall quality of colonoscopy cleaning according to the Boston Bowel Preparation Scale. Patients' tolerance, defecation, adverse events and adenoma detection rate (ADR) were also evaluated.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
2028 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Investigator)
Primary Purpose:
Screening
Official Title:
Improved Bowel Preparation Method for Colonoscopy Based on Different Risk Stratification:a Multicenter, Endoscopist-blinded Randomized Controlled Trial
Actual Study Start Date :
Aug 6, 2020
Anticipated Primary Completion Date :
May 30, 2021
Anticipated Study Completion Date :
May 31, 2021

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: PEG (low-risk patients and high-risk patients)

The dosing regimen of low-risk patients and high-risk patients will only be PEG.

Drug: PEG
Patients began to drink 1 L of PEG at 8:00 PM on the day before colonoscopy at a rate of 250 mL every 10- 15 minutes. On the day of the procedure, patients took the remaining 2 L of PEG 4-6 hours before colonoscopy.
Other Names:
  • only used PEG
  • Experimental: PEG+lactulose (low-risk patients and high-risk patients)

    The dosing regimen of low-risk patients and high-risk patients will be PEG combined with lactulose.

    Drug: PEG+lactulose
    On the day before colonoscopy , Patients took 45 mL lactulose solution at 7:00 PM. And then Patients began to drink 1 L of PEG at 8:00 PM at a rate of 250 mL every 10- 15 minutes. On the day of the procedure, patients took 45 mL lactulose solution and the remaining 2 L of PEG 4-6 hours before colonoscopy.
    Other Names:
  • PEG combined with lactulose
  • Outcome Measures

    Primary Outcome Measures

    1. Boston Bowel Preparation Scale [during colonoscopy]

      Cleanliness of the colon during colonoscopy will be evaluated by the Boston Bowel Preparation Scale which is a 4-point scoring system applied to each of 3 broad regions of the colon: the right side, the transverse section, and the left side. The total BBPS score ranged from 0 to 9. If total BostonBowel Preparation Score ≥6 with each segmental BBPS≥2, we regard it as adequate bowel preparation.

    Secondary Outcome Measures

    1. Adenoma Detection Rate [2 days]

      Diagnosis was confirmed by histologic examination

    2. Rate of adverse events [2 days]

      adverse events, such as vomiting, nausea, headache, abdominal distention,abdominal pain.

    3. Cecal intubation rate [during colonoscopy]

      Colonoscopy reaches cecal region.

    4. Cecal intubation time [during colonoscopy]

      Colonoscopy reaches cecal region.

    5. Withdrawal time [during colonoscopy]

      The time from the cecum to the anus, but excluded time for biopsy performance or removal of polyps.

    6. defecation frequency [2 days]

      Frequency of bowel movement.

    7. Willingness to repeat bowel preparation [2 days]

      The number of patients have a willingness to undergo a repeated bowel preparation if needed.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Adults undergoing colonoscopy.
    Exclusion Criteria:
    • 1.presence of any contraindications for colonoscopy (gastrointestinal obstruction or perforation,severe acute inflammatory bowel disease,toxic megacolon,severe heart failure,unable to swallow,severe heart failure,etc);

    • 2.Patients with galactosemia;

      1. hypersensitivity to any of the ingredients;
    • 4.Pregnancy or lactation;

    • 5.Use of lactulose,prokinetic agents or purgatives within 7 days;

    • 6.Unwilling to sign informed consent.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Renmin Hospital of Wuhan University Wuhan Hubei China 430060

    Sponsors and Collaborators

    • Renmin Hospital of Wuhan University
    • Hubei Hospital of Traditional Chinese Medicine
    • Wuhan Central Hospital
    • Wuhan Third Hospital
    • The General Hospital of Central Theater Command
    • The Third People's Hospital of Hubei
    • Wuhan Puren Hospital
    • Wuhan Puai Hospital
    • Tian You Hospital Affiliated to Wuhan University of Science and Technology
    • Wuhan Red Cross Hospital

    Investigators

    • Principal Investigator: Mingkai Chen, M.D, Renmin Hospital of Wuhan University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    ChenMingkai, Chief physician of Department of Gastroenterology I, Renmin Hospital of Wuhan University
    ClinicalTrials.gov Identifier:
    NCT04582942
    Other Study ID Numbers:
    • 2019-X2-73
    First Posted:
    Oct 12, 2020
    Last Update Posted:
    May 3, 2021
    Last Verified:
    Apr 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by ChenMingkai, Chief physician of Department of Gastroenterology I, Renmin Hospital of Wuhan University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 3, 2021